论文部分内容阅读
目的探讨阿霉素联合紫杉醇调节MAPK/PKC诱导不同种类肺癌细胞凋亡的效果及其机制。方法选取人小细胞肺癌细胞株H446与非小细胞肺癌细胞株A549为实验组,以正常人肺上皮细胞(BEAs-2B)为对照组。CCK-8法检测细胞存活率;检测细胞凋亡蛋白Caspase 3活性;Western blot检测磷酸化MAPK和PKC的蛋白表达水平。同时选取345例肺癌患者,随机接受30天顺铂化疗(158例)和阿霉素联合紫杉醇化疗(187例),检测患者血清MAPK和PKC表达水平,并评价化疗疗效。结果 48 h后,给予阿霉素联合紫杉醇培养的肺癌细胞存活率与对照组相比显著降低,Caspase 3活性显著升高,差异有统计学意义(P<0.05),说明给药后肺癌细胞凋亡明显;与对照组相比,治疗组磷酸化p-p38和p-JNK蛋白表达均明显增加,磷酸化p-PKC蛋白表达明显下降,差异有统计学意义(P<0.05)。阿霉素联合紫杉醇的疗效显著高于单用顺铂,患者血清MAPK水平显著上升,PKC水平显著下降,差异均有统计学意义(P<0.05)。结论阿霉素联合紫杉醇可显著降低肺癌细胞的存活率,促进肺癌细胞凋亡,MAPK/PKC信号通路在此过程中起到重要作用。
Objective To investigate the effect of adriamycin combined with paclitaxel on MAPK / PKC-induced apoptosis in different types of lung cancer cells and its mechanism. Methods Human small cell lung cancer cell line H446 and non-small cell lung cancer cell line A549 were selected as experimental group and normal human lung epithelial cells (BEAs-2B) as control group. The cell viability was detected by CCK-8 assay. The activity of Caspase 3 was detected by Western blot. The protein expression of phosphorylated MAPK and PKC was detected by Western blot. 345 patients with lung cancer were selected and randomly treated for 30 days with cisplatin chemotherapy (158 cases) and doxorubicin combined with paclitaxel chemotherapy (187 cases). The serum levels of MAPK and PKC were measured and the efficacy of chemotherapy was evaluated. Results After 48 h, the survival rate of lung cancer cells cultured with doxorubicin combined with paclitaxel was significantly lower than that of the control group, and the activity of Caspase 3 was significantly increased (P <0.05), indicating that the apoptosis of lung cancer cells Compared with the control group, the expression of phosphorylated p-p38 and p-JNK in the treatment group were significantly increased and the phosphorylated p-PKC protein expression was significantly decreased (P <0.05). The efficacy of doxorubicin combined with paclitaxel was significantly higher than that of cisplatin alone. Serum MAPK levels and PKC levels were significantly decreased (P <0.05). Conclusion Adriamycin combined with paclitaxel can significantly reduce the survival rate of lung cancer cells and promote lung cancer cell apoptosis, MAPK / PKC signaling pathway in this process plays an important role.